SCHEMBL6838004

SCHEMBL6838004

COc1ccccc1NC(=O)c1cc2c(CNCCc3ccccc3)ccc(OC)c2o1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
THRB P10828 1/20 0.49
NPC1 O15118 1/20 0.48
RAB9A P51151 1/20 0.48
SMN1; SMN2 Q16637 1/20 0.48
L3MBTL1 Q9Y468 1/20 0.48
PDE4A P27815 1/20 0.47
PDE4B Q07343 1/20 0.47
PDE4C Q08493 1/20 0.47
PDE4D Q08499 1/20 0.47
KMT2A Q03164 6/20 0.47
MEN1 O00255 2/20 0.46
PKM P14618 1/20 0.46
MAPT P10636 1/20 0.45
GAA P10253 2/20 0.45
CYP3A4 P08684 2/20 0.45
CYP2D6 P10635 2/20 0.45
CYP2C19 P33261 2/20 0.45
CYP1A2 P05177 1/20 0.45
ALOX12 P18054 1/20 0.45
CYP2C9 P11712 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6833213 0.94 THRB (0.50) THRBNPC1RAB9ASMN1; SMN2L3MBTL1
SCHEMBL6836454 0.90 HTT (0.46) NPC1RAB9APDE4APDE4BPDE4C
SCHEMBL6837885 0.88 NPC1 (0.53) THRBNPC1RAB9ASMN1; SMN2KMT2A
SCHEMBL6837814 0.87 MEN1 (0.49) NPC1RAB9ASMN1; SMN2KMT2AMEN1
SCHEMBL6836878 0.86 SMN1; SMN2 (0.47) NPC1RAB9ASMN1; SMN2PDE4APDE4B
SCHEMBL6833204 0.85 SLC6A5 (0.52) NPC1RAB9AKMT2AMEN1CYP3A4
SCHEMBL6837974 0.85 NPC1 (0.45) NPC1RAB9APDE4APDE4BPDE4C
SCHEMBL6839367 0.84 PTGDR2 (0.45) NPC1RAB9ASMN1; SMN2PDE4APDE4B
SCHEMBL6837778 0.83 SMN1; SMN2 (0.52) THRBNPC1RAB9ASMN1; SMN2KMT2A
SCHEMBL6836625 0.83 NPC1 (0.50) THRBNPC1RAB9ASMN1; SMN2KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6716987-B1 PHOSPHODIESTERASE IV INHIBITORS KYOWA HAKKO KOGYO CO., LTD. (JP) 2004-04-06 US disclosed
US-6514996-B2 Derivatives of benzofuran or benzodioxole KYOWA HAKKO KOGYO CO., LTD. (JP) 2003-02-04 US disclosed
US-20020128290-A1 DERIVATIVES OF BENZOFURAN OR BENZODIOXOLE KYOWA HAKKO KOGYO CO., LTD. (JP) 2002-09-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020128290-A1 DERIVATIVES OF BENZOFURAN OR BENZODIOXOLE CBR1, CBR3, CYC1 THRB 1933/4885NPC1 956/4885RAB9A 2778/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.